The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.

Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast ...

Please provide your email address to receive an email when new articles are posted on . A combination of ipilimumab and nivolumab improved PFS by 37% compared with ipilimumab alone. Researchers also ...

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

Please provide your email address to receive an email when new articles are posted on . Datopotamab deruxtecan prolonged PFS by 2 months vs. chemotherapy. Fewer grade 3 or higher adverse events ...

CHICAGO -- Five-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena) progression-free survival (PFS) benefit in ALK-positive non-small cell lung cancer (NSCLC). In the ...

Metformin use in mCRC patients improved PFS during first-line 5-fluorouracil-based chemotherapy, but no OS benefit was observed. The study suggests metformin's potential as an adjunct therapy in mCRC, ...